IGF-1 and IGFBP3 as indirect markers of hepatic insulin resistance and their relation to metabolic syndrome parameters in liver steatosis patients

What Was Tested

The paper reports a study of IGF-1 LR3 in the context of insulin resistance, prediabetes & type 2 diabetes, published as an observational study.

The aim of the present study was to assess insulin-like growth factor 1 (IGF-1) and IGF-binding protein 3 (IGFBP3) as markers of insulin resistance in patients with prediabetes and type 2 diabetes mellitus (TDM2).

Why It Was Studied

This observational clinical study included 76 obese/overweight patients at the age of 45-75 years with T2DM on oral diabetic medication and ultrasonographically or by a computerized tomography (CT) diagnosed liver steatosis.

Correlation analysis was performed between plasma levels of insulin, C-peptide, IGF-1, IGFBP3 and HOMA indexes on the one hand and between plasma levels of ALT, AST, triglyceride, cholesterol, and HDL cholesterol and body mass index (BMI) of patients on the other hand.

Who Took Part

The age groups tagged for this paper are middle-aged adults and older adults.

What Was Measured

Correlation analysis was performed between plasma levels of insulin, C-peptide, IGF-1, IGFBP3 and HOMA indexes on the one hand and between plasma levels of ALT, AST, triglyceride, cholesterol, and HDL cholesterol and body mass index (BMI) of patients on the other hand.

The subject headings attached to it are Metabolic Syndrome, Insulin Resistance, Insulin-Like Growth Factor I, Diabetes Mellitus, Type 2, Insulin-Like Growth Factor Binding Protein 3, C-Peptide and Fatty Liver.

Author keywords: IGF-1, IGFBP3 and liver steatosis.

What This Means in Plain Language

This is an observational study of IGF-1 LR3 in people with insulin resistance, prediabetes & type 2 diabetes.

The publication is from 2023 (Endocrine regulations), a journal based in Germany.

More context: the IGF-1 LR3 compound page, Insulin resistance, prediabetes & type 2 diabetes research.